WO2012054077A3 - Anticorps humains et leurs utilisations diagnostiques et thérapeutiques dans le traitement de troubles neurologiques - Google Patents

Anticorps humains et leurs utilisations diagnostiques et thérapeutiques dans le traitement de troubles neurologiques Download PDF

Info

Publication number
WO2012054077A3
WO2012054077A3 PCT/US2011/001773 US2011001773W WO2012054077A3 WO 2012054077 A3 WO2012054077 A3 WO 2012054077A3 US 2011001773 W US2011001773 W US 2011001773W WO 2012054077 A3 WO2012054077 A3 WO 2012054077A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
treatment
fragments
human antibodies
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/001773
Other languages
English (en)
Other versions
WO2012054077A2 (fr
Inventor
Moses Rodriguez
Arthur E. Warrington
Larry R. Pease
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2011318567A priority Critical patent/AU2011318567B2/en
Priority to ES11834753.3T priority patent/ES2662100T3/es
Priority to NZ609607A priority patent/NZ609607A/en
Priority to CN201180061125.XA priority patent/CN103429260B/zh
Priority to EP17205247.4A priority patent/EP3345619A1/fr
Priority to CA2815046A priority patent/CA2815046C/fr
Priority to EP11834753.3A priority patent/EP2629795B1/fr
Priority to BR112013009673-0A priority patent/BR112013009673B1/pt
Priority to US13/880,415 priority patent/US20130280167A1/en
Application filed by Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Priority to JP2013534892A priority patent/JP6000959B2/ja
Publication of WO2012054077A2 publication Critical patent/WO2012054077A2/fr
Priority to IL225837A priority patent/IL225837B/en
Anticipated expiration legal-status Critical
Publication of WO2012054077A3 publication Critical patent/WO2012054077A3/fr
Priority to AU2017202957A priority patent/AU2017202957B2/en
Priority to IL261742A priority patent/IL261742B/en
Priority to US16/869,344 priority patent/US20200397898A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des éléments de liaison spécifique, en particulier des anticorps humains, et plus particulièrement encore des anticorps recombinants, et leurs fragments, qui sont aptes à se lier à, et à reconnaître, des neurones dans le système nerveux central et à provoquer des réponses dans lesdits neurones du système nerveux central. Lesdits anticorps sont utiles dans la neuroprotection et dans le diagnostic et le traitement de pathologies associées à une lésion, une maladie ou une dégénérescence nerveuse et une maladie neurodégénérative. Les anticorps de l'invention, des régions variables ou des séquences de domaine CDR de ceux-ci, et des fragments de ceux-ci peuvent également être utilisés en thérapie, en association avec des produits chimiothérapeutiques, des modulateurs immunitaires, ou des agents neuroactifs, et/ou avec d'autres anticorps ou fragments de ceux-ci. Lesdits anticorps sont illustrés par les anticorps lgM12 et lgM42 dont les séquences sont indiquées ici.
PCT/US2011/001773 2010-10-19 2011-10-19 Anticorps humains et leurs utilisations diagnostiques et thérapeutiques dans le traitement de troubles neurologiques Ceased WO2012054077A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
US13/880,415 US20130280167A1 (en) 2010-10-19 2011-10-19 Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
NZ609607A NZ609607A (en) 2010-10-19 2011-10-19 Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
JP2013534892A JP6000959B2 (ja) 2010-10-19 2011-10-19 ヒト抗体ならびに神経疾患の処置のためのその診断的および治療的使用
EP17205247.4A EP3345619A1 (fr) 2010-10-19 2011-10-19 Anticorps humains et leurs utilisations diagnostiques et thérapeutiques pour le traitement de maladies neurologiques
CA2815046A CA2815046C (fr) 2010-10-19 2011-10-19 Anticorps humains et utilisations diagnostiques et therapeutiques desdits anticorps pour le traitement de trouble neurologique
EP11834753.3A EP2629795B1 (fr) 2010-10-19 2011-10-19 Anticorps humains et leurs utilisations diagnostiques et thérapeutiques dans le traitement de troubles neurologiques
BR112013009673-0A BR112013009673B1 (pt) 2010-10-19 2011-10-19 Anticorpos igm humanos isolados, método de preparação dos mesmos, kits, composição farmacêutica e ácido nucleico isolado
AU2011318567A AU2011318567B2 (en) 2010-10-19 2011-10-19 Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
CN201180061125.XA CN103429260B (zh) 2010-10-19 2011-10-19 用于治疗神经疾病的人抗体及其诊断和治疗用途
ES11834753.3T ES2662100T3 (es) 2010-10-19 2011-10-19 Anticuerpos humanos y diagnósticos y usos terapéuticos de los mismos para el tratamiento de la enfermedad neurológica
IL225837A IL225837B (en) 2010-10-19 2013-04-18 Human antibodies and their diagnostic and therapeutic uses for the treatment of neurological diseases
AU2017202957A AU2017202957B2 (en) 2010-10-19 2017-05-03 Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
IL261742A IL261742B (en) 2010-10-19 2018-09-13 Human antibodies and their diagnostic and therapeutic uses for the treatment of neurological diseases
US16/869,344 US20200397898A1 (en) 2010-10-19 2020-05-07 Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US45536310P 2010-10-19 2010-10-19
US61/455,363 2010-10-19
US201161537392P 2011-09-21 2011-09-21
US61/537,392 2011-09-21
US201161546634P 2011-10-13 2011-10-13
US61/546,634 2011-10-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/880,415 A-371-Of-International US20130280167A1 (en) 2010-10-19 2011-10-19 Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
US16/869,344 Division US20200397898A1 (en) 2010-10-19 2020-05-07 Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease

Publications (2)

Publication Number Publication Date
WO2012054077A2 WO2012054077A2 (fr) 2012-04-26
WO2012054077A3 true WO2012054077A3 (fr) 2013-10-31

Family

ID=45975788

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/001773 Ceased WO2012054077A2 (fr) 2010-10-19 2011-10-19 Anticorps humains et leurs utilisations diagnostiques et thérapeutiques dans le traitement de troubles neurologiques

Country Status (12)

Country Link
US (2) US20130280167A1 (fr)
EP (2) EP3345619A1 (fr)
JP (5) JP6000959B2 (fr)
CN (2) CN104725507B (fr)
AU (2) AU2011318567B2 (fr)
BR (1) BR112013009673B1 (fr)
CA (2) CA3037903A1 (fr)
ES (1) ES2662100T3 (fr)
HK (1) HK1258028A1 (fr)
IL (2) IL225837B (fr)
NZ (2) NZ609607A (fr)
WO (1) WO2012054077A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104725507B (zh) * 2010-10-19 2018-12-21 梅奥医学教育和研究基金会 用于治疗神经疾病的人抗体及其诊断和治疗用途
CN104379167B (zh) * 2012-04-17 2018-02-13 梅奥医学教育和研究基金会 用于中风和缺血或缺血性病况的人抗体及其特异性结合序列
DK3105250T3 (da) * 2014-02-10 2020-09-28 Igm Biosciences Inc Multispecifikke iga-bindingsmolekyler
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
CA2967026A1 (fr) * 2014-11-07 2016-05-12 Mayo Foundation For Medical Education And Research Traitement de l'hypoxie neonatale et des handicaps ou des effets associes
SG11201707144VA (en) 2015-03-04 2017-09-28 Igm Biosciences Inc Cd20 binding molecules and uses thereof
CA2999284C (fr) 2015-09-30 2023-06-13 Igm Biosciences A/S Molecules de liaison a chaine j modifiee
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
CN112037147B (zh) * 2020-09-02 2024-05-14 上海联影医疗科技股份有限公司 医学图像降噪方法和装置
EP4251202A4 (fr) * 2020-11-30 2025-04-09 Merck Sharp & Dohme LLC Liants d'arginase 1 pour inhiber l'activité de l'arginase 1
CN117679488B (zh) * 2023-12-13 2024-07-05 暨南大学附属第一医院（广州华侨医院） 纳米拮抗剂Au-ADH1在制备治疗脊髓损伤修复药物的用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006218A1 (en) * 1997-11-21 2004-01-08 Genset S.A. Chlamydia pneumoniae polynucleotides and uses thereof
US20060099203A1 (en) * 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
US20070083334A1 (en) * 2001-09-14 2007-04-12 Compugen Ltd. Methods and systems for annotating biomolecular sequences
US7488806B2 (en) * 2006-12-14 2009-02-10 Regeneron Pharmaceuticals, Inc. Human antibodies to human delta like ligand 4
US20090074657A1 (en) * 2007-09-19 2009-03-19 Monoclonal Antibodies Therapeutics Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof
US20090214428A1 (en) * 2005-03-14 2009-08-27 Dimitrov Dimiter S Human Monoclonal Antibodies Against Hendra and Nipah Viruses
WO2009111508A2 (fr) * 2008-03-03 2009-09-11 Dyax Corp. Protéines de liaison à la métalloprotéinase 9 et à la métalloprotéinase 2
US20090274690A1 (en) * 1994-04-29 2009-11-05 Mayo Foundation Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
WO2009155724A2 (fr) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Anticorps stables et solubles inhibant le vegf

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
EP2287191B1 (fr) 2000-05-10 2016-10-12 Mayo Foundation For Medical Education And Research Anticorps igm humains dotés de la capacité d'induire une remyélinisation, utilisations diagnostiques et thérapeutiques pour le système nerveux central
CA2967294C (fr) 2003-05-16 2020-04-28 Mayo Foundation For Medical Education & Research Compositions et procedes comprenant un anticorps monoclonal recombinant qui promeut la remyelinisation du systeme nerveux central
CA2572098C (fr) * 2004-06-30 2015-01-27 Mayo Foundation For Medical Education And Research Anticorps se liant a b7-dc
WO2006029184A2 (fr) * 2004-09-08 2006-03-16 Expression Diagnostics, Inc. Genes permettant de diagnostiquer et de surveiller les troubles associes a l'inflammation
US10202430B2 (en) * 2007-10-18 2019-02-12 Mayo Foundation For Medical Education And Research IgM-mediated receptor clustering and cell modulation
CN104725507B (zh) * 2010-10-19 2018-12-21 梅奥医学教育和研究基金会 用于治疗神经疾病的人抗体及其诊断和治疗用途

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090274690A1 (en) * 1994-04-29 2009-11-05 Mayo Foundation Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US20040006218A1 (en) * 1997-11-21 2004-01-08 Genset S.A. Chlamydia pneumoniae polynucleotides and uses thereof
US20070083334A1 (en) * 2001-09-14 2007-04-12 Compugen Ltd. Methods and systems for annotating biomolecular sequences
US20060099203A1 (en) * 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
US20090214428A1 (en) * 2005-03-14 2009-08-27 Dimitrov Dimiter S Human Monoclonal Antibodies Against Hendra and Nipah Viruses
US7488806B2 (en) * 2006-12-14 2009-02-10 Regeneron Pharmaceuticals, Inc. Human antibodies to human delta like ligand 4
US20090074657A1 (en) * 2007-09-19 2009-03-19 Monoclonal Antibodies Therapeutics Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof
WO2009111508A2 (fr) * 2008-03-03 2009-09-11 Dyax Corp. Protéines de liaison à la métalloprotéinase 9 et à la métalloprotéinase 2
WO2009155724A2 (fr) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Anticorps stables et solubles inhibant le vegf

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WRIGHT ET AL.: "Cellular Mechanisms of Central Nervous System Repair by Natural Autoreactive Monoclonal Antibodies.", ARCH NEUROBIOL, vol. 66, 2009, pages 1456 - 1459, XP055125271 *

Also Published As

Publication number Publication date
BR112013009673B1 (pt) 2022-05-17
IL225837B (en) 2018-10-31
AU2011318567B2 (en) 2017-02-09
JP2020141696A (ja) 2020-09-10
AU2017202957A1 (en) 2017-05-25
JP2016130259A (ja) 2016-07-21
IL225837A0 (en) 2013-07-31
CA2815046A1 (fr) 2012-04-26
NZ624752A (en) 2015-11-27
EP2629795A4 (fr) 2015-03-04
AU2011318567A1 (en) 2013-05-23
EP2629795B1 (fr) 2017-12-06
JP6768728B2 (ja) 2020-10-14
EP2629795A2 (fr) 2013-08-28
NZ609607A (en) 2014-12-24
HK1211593A1 (en) 2016-05-27
JP2022091948A (ja) 2022-06-21
BR112013009673A2 (pt) 2021-02-02
IL261742A (en) 2018-10-31
US20130280167A1 (en) 2013-10-24
JP6000959B2 (ja) 2016-10-05
EP3345619A1 (fr) 2018-07-11
CN103429260B (zh) 2016-08-10
JP2018099130A (ja) 2018-06-28
IL261742B (en) 2020-03-31
CN103429260A (zh) 2013-12-04
CA2815046C (fr) 2019-05-14
CN104725507B (zh) 2018-12-21
HK1258028A1 (en) 2019-11-01
CA3037903A1 (fr) 2012-04-26
US20200397898A1 (en) 2020-12-24
AU2017202957B2 (en) 2019-06-06
JP2014504263A (ja) 2014-02-20
CN104725507A (zh) 2015-06-24
ES2662100T3 (es) 2018-04-05
WO2012054077A2 (fr) 2012-04-26

Similar Documents

Publication Publication Date Title
WO2012045882A3 (fr) Composition pharmaceutique
WO2013106485A3 (fr) Régions déterminant la complémentarité ultralongues et utilisations associées
WO2009013543A3 (fr) Agents de liaisons ciblés dirigés vers kdr, et utilisations de ceux-ci - 035
IN2014MN02274A (fr)
WO2012088290A3 (fr) Protéines de liaison à trois domaines variables et leurs utilisations
MX356800B (es) Anticuerpo tau humanizado.
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
HK1200321A1 (en) Bispecific immunobinders directed against tnf and il-17
WO2011106300A3 (fr) Thérapie anti-angiogénique pour le traitement du cancer des ovaires
WO2012018790A3 (fr) Immunoglobulines à double domaine variable et utilisations associées
WO2012061558A3 (fr) Immunoglobulines à double domaine variable et leurs utilisations
WO2012027570A3 (fr) Immunoglobulines à deux domaines variables et leurs utilisations
WO2012061374A3 (fr) Immunoglobulines à double domaine variable et utilisations de celles-ci
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
MY164579A (en) Safe and functional humanized antibodies
EP2915818A3 (fr) Immunoglobuline à double domaine variable et ses utilisations
WO2011163478A3 (fr) Immunoglobulines à double domaine variable et utilisations associées
WO2013102042A3 (fr) Protéines à double liaison spécifique dirigées contre l'il-13 et/ou l'il-17
IL261742B (en) Human antibodies and their diagnostic and therapeutic uses for the treatment of neurological diseases
WO2015191934A8 (fr) Barrière hémato-encéphalique pénétrant des protéines de liaison spécifiques doubles pour le traitement de maladies cérébrales et neurologiques
PH12014502582B1 (en) Anti-TG2 Antibodies and Methods for Using the Same
WO2010072740A3 (fr) Agents de liaison ciblés dirigés contre α5β1 et leurs applications
WO2010135521A3 (fr) Compositions et procédés pour le traitement et le diagnostic de la grippe
WO2014053110A3 (fr) Peptide pour le traitement et le diagnostic précoce de la maladie d'alzheimer et d'autres tauopathies
WO2011080050A3 (fr) Molécules de liaison

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11834753

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2815046

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013534892

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011834753

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011318567

Country of ref document: AU

Date of ref document: 20111019

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13880415

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013009673

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112013009673

Country of ref document: BR

Free format text: COM BASE NA RESOLUCAO 81/2013, SOLICITA-SE QUE SEJA APRESENTADO, EM ATE 60 (SESSENTA) DIAS, DECLARACAO REFERENTE AO CONTEUDO DA LISTAGEM DE SEQUENCIA, NOS MOLDES DA RESOLUCAO NO 187 DE 27/04/2017, POIS A DECLARACAO APRESENTADA NA PETICAO NO 020130033694 DE 19/04/2013 NAO ESTA ASSINADA.

ENP Entry into the national phase

Ref document number: 112013009673

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130419